skip to content
Emerging drugs and targets for Alzheimer's disease. Volume 1, Beta-amyloid, tau protein and glucose metabolism Preview this item
ClosePreview this item
Checking...

Emerging drugs and targets for Alzheimer's disease. Volume 1, Beta-amyloid, tau protein and glucose metabolism

Author: Ana Martínez
Publisher: Cambridge : Royal Society of Chemistry, 2010.
Series: RSC drug discovery; RSC drug discovery series.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Additional Physical Format: Print version:
Emerging drugs and targets for Alzheimer's disease. Volume 1, Beta-amyloid, tau protein and glucose metabolism.
Cambridge : Royal Society of Chemistry, 2010
(OCoLC)540182463
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Ana Martínez
ISBN: 9781849731065 1849731063 9781849730631 1849730636
OCLC Number: 642690079
Description: 1 online resource (318 pages).
Contents: Beta-Amyloid as target --
Chapter 1: The amyloid hypothesis of AD and prospects for therapeutics --
Chapter 2: Targeting Alzheimer's?-Secretase: Genetic and Chemical Modulation --
Chapter 3: Cholesterol and AD: the molecules, the targets --
Chapter 4: The Bimodal Features of Butyrylcholinesterase in Cholinergic Neurotransmission and Amyloid Suppression --
Chapter 5: Scyllo-inositol, a potential therapy for Alzheimer's disease --
Chapter 6: Immunotherapeutic strategies toward treatment of AD --
Tau protein as target --
Chapter 7: Alzheimer Neurofibrillary Degeneration: Pivotal Role and Therapeutic Targets --
Chapter 8: Multiple roles of glycogen synthase kinase-3 in AD --
Chapter 9: Tau protein kinases inhibitors: from the bench to the clinical trials --
Chapter 10: Activating PP2A as a therapeutic intervention strategy in AD --
Chapter 11: Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies --
Glucose Metabolism as target --
Chapter 12: Insulin Insulin Resistance and neurodegeneration: Type 2 versus type 3 diabetes mellitus --
Chapter 13: Insulin-like Growth Factor I as a disease-modifying therapy in Alzheimer's disease --
Chapter 14: Ketone bodies as a therapeutic for Alzheimer's disease.
Series Title: RSC drug discovery; RSC drug discovery series.
Responsibility: editor, Ana Martinez.

Abstract:

This volume describes the discovery and development history of the most promising drugs now in development for combating Alzheimer's disease.  Read more...

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/642690079> # Emerging drugs and targets for Alzheimer's disease. Volume 1, Beta-amyloid, tau protein and glucose metabolism
    a schema:Book, schema:CreativeWork, schema:MediaObject ;
    library:oclcnum "642690079" ;
    library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/412027654#Place/cambridge> ; # Cambridge
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/enk> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/412027654#Topic/neurology_&_clinical_neurophysiology> ; # Neurology & clinical neurophysiology
    schema:about <http://id.worldcat.org/fast/806536> ; # Alzheimer's disease--Chemotherapy
    schema:about <http://dewey.info/class/616.831061/e22/> ;
    schema:about <http://id.worldcat.org/fast/898709> ; # Drug targeting
    schema:about <http://experiment.worldcat.org/entity/work/data/412027654#Topic/health_&_fitness_diseases_alzheimer_s_&_dementia> ; # HEALTH & FITNESS--Diseases--Alzheimer's & Dementia
    schema:about <http://experiment.worldcat.org/entity/work/data/412027654#Topic/alzheimer_s_disease_chemotherapy> ; # Alzheimer's disease--Chemotherapy
    schema:about <http://experiment.worldcat.org/entity/work/data/412027654#Topic/medical_neurology> ; # MEDICAL--Neurology
    schema:about <http://id.worldcat.org/fast/808153> ; # Amyloid beta-protein
    schema:bookFormat schema:EBook ;
    schema:contributor <http://viaf.org/viaf/162547980> ; # Ana Martínez
    schema:datePublished "2010" ;
    schema:description "Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism will be an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field."@en ;
    schema:description "Beta-Amyloid as target -- Chapter 1: The amyloid hypothesis of AD and prospects for therapeutics -- Chapter 2: Targeting Alzheimer's?-Secretase: Genetic and Chemical Modulation -- Chapter 3: Cholesterol and AD: the molecules, the targets -- Chapter 4: The Bimodal Features of Butyrylcholinesterase in Cholinergic Neurotransmission and Amyloid Suppression -- Chapter 5: Scyllo-inositol, a potential therapy for Alzheimer's disease -- Chapter 6: Immunotherapeutic strategies toward treatment of AD -- Tau protein as target -- Chapter 7: Alzheimer Neurofibrillary Degeneration: Pivotal Role and Therapeutic Targets -- Chapter 8: Multiple roles of glycogen synthase kinase-3 in AD -- Chapter 9: Tau protein kinases inhibitors: from the bench to the clinical trials -- Chapter 10: Activating PP2A as a therapeutic intervention strategy in AD -- Chapter 11: Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies -- Glucose Metabolism as target -- Chapter 12: Insulin Insulin Resistance and neurodegeneration: Type 2 versus type 3 diabetes mellitus -- Chapter 13: Insulin-like Growth Factor I as a disease-modifying therapy in Alzheimer's disease -- Chapter 14: Ketone bodies as a therapeutic for Alzheimer's disease."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/412027654> ;
    schema:genre "Electronic books"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/412027654#Series/rsc_drug_discovery_series> ; # RSC drug discovery series.
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/412027654#Series/rsc_drug_discovery> ; # RSC drug discovery
    schema:isSimilarTo <http://www.worldcat.org/oclc/540182463> ;
    schema:name "Emerging drugs and targets for Alzheimer's disease. Volume 1, Beta-amyloid, tau protein and glucose metabolism"@en ;
    schema:productID "642690079" ;
    schema:publication <http://www.worldcat.org/title/-/oclc/642690079#PublicationEvent/cambridge_royal_society_of_chemistry_2010> ;
    schema:publisher <http://experiment.worldcat.org/entity/work/data/412027654#Agent/royal_society_of_chemistry> ; # Royal Society of Chemistry
    schema:url <http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=519307> ;
    schema:url <http://dx.doi.org/10.1039/9781849731065> ;
    schema:url <https://nls.ldls.org.uk/welcome.html?ark:/81055/vdc_100035663446.0x000001> ;
    schema:workExample <http://dx.doi.org/10.1039/9781849731065> ;
    schema:workExample <http://worldcat.org/isbn/9781849731065> ;
    schema:workExample <http://worldcat.org/isbn/9781849730631> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/642690079> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/412027654#Agent/royal_society_of_chemistry> # Royal Society of Chemistry
    a bgn:Agent ;
    schema:name "Royal Society of Chemistry" ;
    .

<http://experiment.worldcat.org/entity/work/data/412027654#Series/rsc_drug_discovery> # RSC drug discovery
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/642690079> ; # Emerging drugs and targets for Alzheimer's disease. Volume 1, Beta-amyloid, tau protein and glucose metabolism
    schema:name "RSC drug discovery" ;
    .

<http://experiment.worldcat.org/entity/work/data/412027654#Series/rsc_drug_discovery_series> # RSC drug discovery series.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/642690079> ; # Emerging drugs and targets for Alzheimer's disease. Volume 1, Beta-amyloid, tau protein and glucose metabolism
    schema:name "RSC drug discovery series." ;
    .

<http://experiment.worldcat.org/entity/work/data/412027654#Topic/health_&_fitness_diseases_alzheimer_s_&_dementia> # HEALTH & FITNESS--Diseases--Alzheimer's & Dementia
    a schema:Intangible ;
    schema:name "HEALTH & FITNESS--Diseases--Alzheimer's & Dementia"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/412027654#Topic/medical_neurology> # MEDICAL--Neurology
    a schema:Intangible ;
    schema:name "MEDICAL--Neurology"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/412027654#Topic/neurology_&_clinical_neurophysiology> # Neurology & clinical neurophysiology
    a schema:Intangible ;
    schema:name "Neurology & clinical neurophysiology"@en ;
    .

<http://id.worldcat.org/fast/806536> # Alzheimer's disease--Chemotherapy
    a schema:Intangible ;
    schema:name "Alzheimer's disease--Chemotherapy"@en ;
    .

<http://id.worldcat.org/fast/808153> # Amyloid beta-protein
    a schema:Intangible ;
    schema:name "Amyloid beta-protein"@en ;
    .

<http://id.worldcat.org/fast/898709> # Drug targeting
    a schema:Intangible ;
    schema:name "Drug targeting"@en ;
    .

<http://viaf.org/viaf/162547980> # Ana Martínez
    a schema:Person ;
    schema:birthDate "1961" ;
    schema:familyName "Martínez" ;
    schema:givenName "Ana" ;
    schema:name "Ana Martínez" ;
    .

<http://worldcat.org/isbn/9781849730631>
    a schema:ProductModel ;
    schema:isbn "1849730636" ;
    schema:isbn "9781849730631" ;
    .

<http://worldcat.org/isbn/9781849731065>
    a schema:ProductModel ;
    schema:isbn "1849731063" ;
    schema:isbn "9781849731065" ;
    .

<http://www.worldcat.org/oclc/540182463>
    a schema:CreativeWork ;
    rdfs:label "Emerging drugs and targets for Alzheimer's disease. Volume 1, Beta-amyloid, tau protein and glucose metabolism." ;
    schema:description "Print version:" ;
    schema:isSimilarTo <http://www.worldcat.org/oclc/642690079> ; # Emerging drugs and targets for Alzheimer's disease. Volume 1, Beta-amyloid, tau protein and glucose metabolism
    .

<http://www.worldcat.org/title/-/oclc/642690079>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/642690079> ; # Emerging drugs and targets for Alzheimer's disease. Volume 1, Beta-amyloid, tau protein and glucose metabolism
    schema:dateModified "2018-09-12" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.